Treatment of warfarin-associated coagulopathy with vitamin K

Expert Review of Hematology

Volumn 4, Issue 6, 2011, Pages 657-667

  Patriquin, Christopher ^a   Crowther, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

anticoagulation; bleeding; coagulopathy; coumarin; INR; prothrombin complex concentrates; vitamin K; vitamin K antagonists; warfarin; warfarin associated coagulopathy

Indexed keywords

APIXABAN; DABIGATRAN; FRESH FROZEN PLASMA; PHENPROCOUMON; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; TRANEXAMIC ACID; VITAMIN K GROUP; WARFARIN;

ANAPHYLAXIS; ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING DISORDER; DRUG DOSAGE FORM COMPARISON; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; GENETIC POLYMORPHISM; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; ORAL BLEEDING; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; WARFARIN ASSOCIATED COAGULOPATHY;

BLOOD COAGULATION DISORDERS; HUMANS; INTERNATIONAL NORMALIZED RATIO; VITAMIN K; WARFARIN;

EID: 81255211420     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.59     Document Type: Review

References (60)

1. Kessler CM. Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J. Thromb. Haemost. 4(5), 963-966 (2006).
2. Vigue B. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit. Care 13(2), 209 (2009).
3. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 24(10), 1311-1316 (2004). (Pubitemid 39304994)
4. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J. Am. Coll. Cardiol. 41(4 Suppl.), 62S-69S (2003). (Pubitemid 36223349)
5. Hirsh J, Dalen J, Anderson DR et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119(1 Suppl.), 8S-21S (2001). (Pubitemid 32154192)
6. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl.), 160S-198S (2008). (Pubitemid 351892967)
7. Samsa GP, Matchar DB, Goldstein LB et al. Quality of anticoagulation management among patients with atrial fibrillation: Results of a review of medical records from 2 communities. Arch. Intern. Med. 160(7), 967-973 (2000). (Pubitemid 30191925)
8. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348(9028), 633-638 (1996).
9. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 127(5), 1515-1522 (2005). (Pubitemid 46218774)
10. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: A systematic review and meta-analysis. CMAJ 179(3), 235-244 (2008).
11. Wan Y, Heneghan C, Perera R et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ. Cardiovasc. Qual. Outcomes 1(2), 84-91 (2008).
12. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J. Thromb. Haemost. 3(5), 955-961 (2005). (Pubitemid 41632826)
13. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. Br. J. Haematol. 132(3), 277-285 (2006). (Pubitemid 43381534)
14. Narum S, Solhaug V, Myhr K, Johansen PW, Brors O, Kringen MK. Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system. Br. J. Clin. Pharmacol. 71(2), 254-262 (2011).
15. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3(4), 692-694 (2005). (Pubitemid 41647882)
16. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348(9025), 423-428 (1996). (Pubitemid 26267872)
17. Douketis JD, Berger PB, Dunn AS et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl.), 299S-339S (2008).
18. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch. Intern. Med. 160(11), 1612-1617 (2000). (Pubitemid 30367900)
19. Oden A, Fahlen M. Oral anticoagulation and risk of death: A medical record linkage study. BMJ 325(7372), 1073-1075 (2002). (Pubitemid 35351801)
20. Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H. Warfarin and vitamin K intake in the era of pharmacogenetics. Br. J. Clin. Pharmacol. 70(2), 164-170 (2010).
21. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J. Gen. Intern. Med. 24(5), 656-664 (2009).
22. Burmester JK, Berg RL, Yale SH et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet. Med. 13(6), 509-518 (2011).
23. Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared with patients with stable control of anticoagulation. Thromb. Haemost. 93(5), 872-875 (2005). (Pubitemid 40691544)
24. de Assis MC, Rabelo ER, Avila CW, Polanczyk CA, Rohde LE. Improved oral anticoagulation after a dietary vitamin k-guided strategy: A randomized controlled trial. Circulation 120(12), 1115-1122 (2009).
25. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109(6), 2419-2423 (2007). (Pubitemid 46425883)
26. Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J. Thromb. Haemost. 5(10), 2043-2048 (2007). (Pubitemid 47450022)
27. Ford SK, Moll S. Vitamin K supplementation to decrease variability of international normalized ratio in patients on vitamin K antagonists: A literature review. Curr. Opin. Hematol. 15(5), 504-508 (2008).
28. Lee A, Crowther M. Practical issues with vitamin K antagonists: Elevated INRs, low time-in-therapeutic range, and warfarin failure. J. Thromb. Thrombolysis 31(3), 249-258 (2011).
29. Crowther MA, Ageno W, Garcia D et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: A randomized trial. Ann. Intern. Med. 150(5), 293-300 (2009).
30. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: A systematic review and proposed treatment algorithms. J. Thromb. Haemost. 4(9), 1853-1863 (2006). (Pubitemid 44226758)
31. Crowther MA, Douketis JD, Schnurr T et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann. Intern. Med. 137(4), 251-254 (2002).
32. Dezee KJ, Shimeall WT, Douglas KM, Shumway NM, OMalley PG. Treatment of excessive anticoagulation with phytonadione (vitamin K): A meta-analysis. Arch. Intern. Med. 166(4), 391-397 (2006).
33. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann. Intern. Med. 122(1), 40-42 (1995).
34. Schulman S, Elbazi R, Zondag M, ODonnell M. Clinical factors influencing normalization of prothrombin time after stopping warfarin: A retrospective cohort study. Thromb. J. 6, 15 (2008).
35. Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J. Thromb. Thrombolysis 24(2), 93-97 (2007).
36. Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J. Am. Coll. Cardiol. 47(4), 804-808 (2006). (Pubitemid 43243105)
37. Dentali F, Ageno W. Management of coumarin-associated coagulopathy in the non-bleeding patient: A systematic review. Haematologica 89(7), 857-862 (2004). (Pubitemid 38981347)
38. Ageno W, Garcia D, Silingardi M, Galli M, Crowther M. A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves. J. Am. Coll. Cardiol. 46(4), 732-733 (2005). (Pubitemid 41132707)
39. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin. Br. J. Haematol. 115(1), 145-149 (2001). (Pubitemid 32995108)
40. Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb. Haemost. 79(6), 1116-1118 (1998). (Pubitemid 28297157)
41. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: A prospective randomized controlled study. Arch. Intern. Med. 163(20), 2469-2473 (2003). (Pubitemid 37385789)
42. Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 20(10), 1159-1166 (2000).
43. Gunther KE, Conway G, Leibach L, Crowther MA. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR<10. Thromb. Res. 113(3-4), 205-209 (2004). (Pubitemid 38609405)
44. Crowther MA, Garcia D, Ageno W et al. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb. Haemost. 104(1), 118-121 (2010).
45. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J. Thromb. Thrombolysis 29(2), 171-181 (2010).
46. Garcia D, Crowther MA, Ageno W. Practical management of coagulopathy associated with warfarin. BMJ 340, c1813 (2010).
47. Schulman S. Clinical practice. Care of patients receiving long-term anticoagulant therapy. N. Engl. J. Med. 349(7), 675-683 (2003). (Pubitemid 36980605)
48. Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus. Med. Rev. 18(3), 184-188 (2004). (Pubitemid 38962487)
49. Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review (2008). Hematology Am. Soc. Hematol. Educ. Program 2008, 36-38 (2008).
50. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus. Med. Rev. 21(1), 37-48 (2007). (Pubitemid 44881256)
51. Spahn DR, Cerny V, Coats TJ et al. Management of bleeding following major trauma: A European guideline. Crit. Care 11(1), R17 (2007).
52. Rossaint R, Bouillon B, Cerny V et al. Management of bleeding following major trauma: An updated European guideline. Crit. Care 14(2), R52 (2010).
53. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb. Res. 121(1), 9-16 (2007). (Pubitemid 350025993)
54. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am. J. Hematol. 83(2), 137-143 (2008).
55. Vang ML, Hvas AM, Ravn HB. Urgent reversal of vitamin K antagonist therapy. Acta Anaesthesiol. Scand. 55(5), 507-616 (2011).
56. Lin Y, Callum J. Emergency reversal of warfarin anticoagulation. CMAJ 182(18), 2004 (2010).
57. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): A 5-year retrospective review. Ann. Allergy Asthma Immunol. 89(4), 400-406 (2002). (Pubitemid 36188012)
58. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann. Intern. Med. 135(6), 393-400 (2001). (Pubitemid 32845864)
59. Deloughery TG. Practical aspects of the oral new anticoagulants. Am. J. Hematol. 86(7), 586-590 (2011).
60. Brenner B, Hoffman R. Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood Rev. 25(5), 215-221 (2011).